

REFERENCES

- Acien P, Quereda F, Matallin P, et al.** Insulin, androgens and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. *Fertil Steril* 1999; 72:32-40.
- Adams J, Franks S, Polson DW, et al.** Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. *Lancet* 1985; 2: 1375-1379.
- Adams J, Polson DW, Franks S.** Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. *BMJ* 1986; 293: 355-359.
- Ali Hassan H, El-Gezeiry D and Nafaa TM:** Improved responsiveness of PCOS patients to clomiphene after CYP17a inhibitor. *J Assist Reprod Genet* 2001; 18, 608-611.
- Allen SE, Potter HD, Azziz R.** Prevalence of hyperandrogenemia among nonhirsute olig-ovulatory women. *Fertil Steril* 1997; 67: 569-572.
- Andrea D. Coviello, Richard S. Legro, Andrea Dunaif.** Adolescent girls with polycystic ovary syndrome, *Journal of Clinical Endocrinology & Metabolism*. First Published October 25, 2005 as doi: 10.1210/jc.2005-1666.
- Apridonize T, Essah PA, Iuorno MJ, Nestler, JE.** Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. *J Clin Endocrinol Metab*, 2004.
- Apter D, Butzow T, Laughlin GA, et al.** Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: Relevance to the developmental phase of polycystic ovary syndrome. *J Clin Endocrinol Metab* 1994; 79:119-125.
- Arroyo A. Laughlin GA, Morales AJ, et al.** Inappropriate gonadotropin secretion in polycystic ovary syndrome: Influence of adiposity. *J Clin Endocrinol Metab* 1997; 82:3728-3733.

- Austin MA, Breslow JL, Hennekens CH, et al.** Low-density lipoprotein subclass patterns and risk of myocardial infarction. *J Am Med Assoc* 1988; 260: 1917-21.
- Azziz R, Dewailly D, Owerbach D.** Nonclassic adrenal hyperplasia: Current concepts. Clinical review 56. *J Clin Endocrinol Metab* 1994; 78:810-815.
- Azziz R, Rittmaster RS, Fox LM, et al.** Role of the ovary in the adrenal androgen excess of hyperandrogenic women. *Fertil Steril* 1998; 69: 851-859.
- Balen AH, Conway GS, Kaltsas G, et al.** Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. *Hum Reprod* 1995; 10:2107-2111.
- Balen AH, Jacobs HS.** A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. *Fertil Steril* 1994; 62:921-925.
- Balen AH.** The pathogenesis of polycystic ovarian syndrome: the enigma unravels. *Lancet* 1999; 354: 966-967.
- Baranowska B, Radzikowska M, Wasilewska- Dziubinska E, et al.** Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. *Gynecol Endocrinol* 1999; 13:344-351.
- Baranowska B, Wasilewska- Dziubinska E, Radzikowska M, et al.** Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa. *Metabolism* 1997; 46:1384-1389.
- Barbieri RL, Ryan KJ.** Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiologic features. *Am J Obstet Gynecol* 1983; 147:90-101.
- Barnes RB, Rosensfield RL, Ehrmann DA, et al.** Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women. *J Clin Endocrinol Metab* 1994; 79: 1328-1333.

- Bass KM, Newschaffer CJ, Klag MJ, Bush TL.** Plasma lipoprotein levels as predictors of cardiovascular death in women. *Arch Intern Med.* 1993; 153:2209-2216.
- Baure J, Isojarvi JI, Herzog AG ET AL.** Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. *J Neurol Neurosurg psychiatry* 2002; 73: 121-125.
- Belchetz PE, Plant TM, Nakai Y, et al.** Hypophysial responses to continuous and intermittent delivery of hypophthalamic gonadotropin-releasing hormone. *Science* 1978; 202: 631-633.
- Bengtsson C, Bjorkelund C, Lapidus L, Lissner L.** Association of Serum lipid concentration and obesity with mortality in women. Twenty years follow-up of participants in prospective population study in Gothenberg, Sweden. *Br Med J*; 1993; 307:1385-8.
- Berga SL, Guzick DS, Winters SJ.** Increased luteinizing hormone and α -subunit secretion in women with hyperandrogenic ovulation. *J Clin Endocrinol Metab* 1993; 77:895-901.
- Berga SL, Yen SSC.** Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 1989; 30: 177-184.
- Bohlke K, Cramer DW, Barbieri RL.** Relation of luteinizing hormone levels to body mass index in premenopausal women. *Fertil Steril* 1998; 69:500-504.
- Buckett WM, Bouzayen R, Watkin KL, et al.** Ovarian stromal echogenicity in women with normal and polycystic ovaries. *Hum Reprod* 1999; 14:618-621.
- Campebell, M.J. and Machin, D.** Medical statistics. A common sense approach. 2nd edition John Wiley and Sons publication: New York, chister, Brisbane, toronto and singapore, 1993.
- Campos, H., Sacks, F.M., Walsh, B.W., Schiff, I., O'Hanesian, M.A. and Krauss, R.M.** Differential effects of estrogen on LDL subclasses in healthy postmenopausal women. *Metabolism*, 1993; 42, 1153-1158.

- Carmina E, Koyama T, Chang L, et al.** Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? *Am J Obstet Gynecol* 1992; 167:1807-1812.
- Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA.** Metabolic syndrome in polycystic ovary syndrome, *Eur J Endocrinol*. 2006 Jan; 154 (1): 141-5.
- Carmina E, Wong L, Chang L, et al.** Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. *Hum Reprod* 1997; 12:905-909.
- Cioffi JA, Shafer AW, Zupancic TJ, et al.** Novel B219/OB receptor isoforms possible: role of leptin in hematopoiesis and reproduction. *Nat Med* 1996; 2:585-589.
- Clayton, RN, Ogden V, Hodgkinson J et al.** How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? *Clin Endocrinol* 1992; 37: 127-134.
- Clevidence BA, Reichman ME, Judd IT, et al.** Effects of alcohol consumption of lipoproteins of premenopausal women. A controlled diet study. *Arterioscl Thromb Vasc Biol*. 1995; 15; 179-184.
- Conway GS, Agrawal R, Betteridge DJ, Jacobs HS.** Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. *Clin Endocrinol*. 1992; 37; 119-125.
- Conway GS, Honour JW, Jacobs HS.** Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients. *Clin Endocrinol* 1989; 30: 459-470.
- Conway, G.S., Agrawal, R., Betteridge, D.J. and Jacobs, H.S.** Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. *Clinical Endocrinology* 1992; 37,119-125.
- Cook S, Weizman M, Auinger P, Nguyen M, Dietz WH.** Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. *Arch Pediatr Adolesc Med* 2002; 157:821-7.

- Coonrod DV, Rizkallah TH.** Virilizing adrenal Carcinoma in a woman of reproductive age: A case presentation and literature review. *Am J Gynecol* 1995; 172: 1912-1914.
- Coppack SW, Evans RD, Fisher RM.** Adipose tissue metabolism in obesity. Lipase action in vivo before and after a mixed meal. *Metabolism* 1992; 41: 264-72.
- Cruz ML, Goran MI.** The metabolic syndrome in children and adolescents. *Curr Diab Rep* 2004; 4: 53-62.
- Dahlgren, E., Johansson, S., Lindstedt, G., Knutsson, F., Oden, A., Janson, P.O., Mattson, L.A., Crona, N. and Lundberg, P.A.** Women with polycystic ovary syndrome wedge resected in 1956-65: a long-term follow-up focusing on natural history and circulating hormones. *Fertility Sterility* 1992; 57, 505-513.
- De Geyter C, De Geyter M, Huber PR, Nieschlag E and Holzgreve W:** Progesterone serum levels during the follicular phase of the menstrual cycle originate from the crosstalk between the ovaries and the adrenal cortex. *Hum Reprod* 2002; 17,933-939.
- De Leo V, Lansetta D, D'Antona D, et al.** Hormonal effects of flutamide in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1998; 83:99-102.
- Derksen J, Nagesser SK, Meinders AE, et al.** Identification of virilizing adrenal tumors in hirsute women. *N Engl J Med* 1994; 331:968-973.
- Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C.** Arterioscler Thromb 1990; 10:497-511. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. *Endocrinology* 1993; 132:86-93.
- Dieudonne MN, Pecquery R, Boumediene A, Leneuve MC, Giudicelli Y.** Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. *Am J Physiol* 1998; 274:C164-52.
- Doi SA, Towers PA, Scott CJ and Al-Shoumer KA:** s PCOS: an ovarian disorder that leads to dysregulation in the hypothalamic-pituitary-adrenal axis? *Eur J Obstet Gynecol Reprod Biol* 2005; 118,4-16.

- Doldi N, Gessi A, Destefani A, Calzi F and Ferrari A:** Polycystic ovary syndrome: anomalies in progesterone production. *Hum Reprod* 1998; 13:290-293.
- Dumesic DA, Abbott DH, Eisner JR, et al.** Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. *Fertil Steril* 1997; 67:155-163.
- Dunaif A, Graf M, Mandeli J, et al.** Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/ or hyperinsulinemia. *J Clin Endocrinol Metab* 1987; 65:499-507.
- Dunaif A, Green G, Phelps RG, et al.** Acanthosis nigricans, insulin action, and hyperandrogenism: Clinical, histological, and biochemical findings. *J Clin Endocrinol Metab* 1991; 73:590-595.
- Dunaif A.** Insulin resistance and the polycystic ovarian syndrome: mechanisms and implications for pathogenesis. *Endocrine Rev* 1997; 18: 774-800.
- Dunaif A.** Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev* 1997; 18: 774-800.
- Eden JA, Place J, Carter GD, et al.** The diagnosis of polycystic ovaries in subfertile women. *Br J Obstet Gynaecol* 1989; 96:809-815.
- Ehrmann DA, Barnes RB, Roesnfield RL., et al.** Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care* 1999; 22: 141-146.
- Ehrmann DA, Rosenfield RL., Barnes RB, et al.,** Detection of functional ovarian hyperandrogenism in women with androgen excess. *N Engl J Med* 1992; 327:157-162.
- Erickson JC, Clegg KE, Palamiter RD.** Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. *Nature* 1996; 381: 415-421.
- Farquhar CM, Birdsall MA, Manning P et al.** The prevalence of polycystic ovaries on ultrasound scanning in a population of

- randomly selected women. Aust NZ J Obstet Gynaecol 1994; 34: 67-72.
- Fauser BC, Pache TD, Lamberts SW, et al.** Serum Bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 1991; 73:811-817.
- Fernandez- Galaz MC, Morschl E, Chowen JA, et al.** Role of astroglia and insulin like growth factor-I in gonadal hormone- dependent synaptic plasticity. Brain Res Bull 1997; 44: 525-531.
- Figlewicz DP, Brot MD, McCall AL, et al.** Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat. A Molecular Study. Brain Res 1996; 736: 54- 60.
- Ford ES, Giles WH, Dietz WH.** Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. 2002; Jama 287: 356-9.
- Foresta C, Marra S, Scanelli G, et al.** Gonadal steroids and opioid control of gonadotropin secretion in man. Fertil Steril 1983; 40:798.
- Fox R.** Transvaginal ultrasound appearance of the ovary in normal women and hirsute women with oligomenorrhoea. Aust N Z J Obstet Gynaecol 1999; 39:63-68.
- Franks S. McCarthy MI, Hardy K.** Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2005; Dec 22.
- Franks S.** Polycystic ovary syndrome. N Engl J Med 1995; 3: 853-61.
- Frayn KN.** Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993; 4: 197-204.
- Friedlander, Y., Kidron, M., Caslake, M., Lamb, T., McConnell, M. and Bar-On, H.** Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis 2000; 148, 141-149.
- Furuhashi M, Suganuma N and Nishimori K:** Successful pregnancy in a patient having high basal serum levels of sex steroid hormones. Arch Gynecol Obstet 2002; 267, 46-48.

- Futterweit W, Deligdisch L.** Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. *J Clin Endocrinol Metab* 1986; 62:16-21.
- Gardner, C.D., Fortmann, S.P. and Krauss, R.M.** Association of small LDL particles with the incidence of coronary artery disease in men and women. *Journal of the American Medical Association* 1996; 276, 875-881.
- Genton P, Bauer J, Duncan S et al.** On the association between valproate and polycystic ovary syndrome. *Epilepsia* 2001; 42: 305-310.
- Gilling-Smith C, Willis DS, Franks S.** Oestradiol feedback stimulation of androgen biosynthesis by human theca cells. *Hum Reprod* 1997; 2:1621-1621-1628.
- Glickman SP, Rosenfield RL, Bergenstal RM, et al.** Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women. *J Clin Endocrinol Metab* 1982; 55: 251-257.
- Goldzieher JW, Axelrod LR.** Clinical and biochemical features of polycystic ovarian disease. *Fertil Steril* 1963; 14:631-653.
- Govind A, Obhrai MS, Clayton RN.** Polycystic ovaries are inherited as an autosomal dominant trait: Analysis of 29 polycystic ovary syndrome and 10 control families. *J Clin Endocrinol Metab* 1999; 84:38-43.
- Graf MJ, Richards CJ, Brown V, et al.** The independent effects of hyperandrogenaemia, hyperinsulinaemia and obesity on lipid and lipoprotein profiles in women. *Clin Endocrinol (Oxf)* 1990; 33:119-31.
- Grasinger CC, Wild RA, Parker IJ.** Vulvar acanthosis nigricans: A marker for insulin resistance in hirsute women. *Fertil Steril* 1993; 59:583-586.
- Griffin, B.A., Freeman, D.J., Tait, G.W., Thomson, J., Caslake, M.J., Packard, C.J. & Shepherd, J.** Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfraction: Relative contribution of small, dense LDL to coronary heart disease risk. *Atherosclerosis* 1994; 106, 241-253.
- Guzick DS, Talbott E, Sutton- Tyrrell K, et al.** Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a

case-control study. *Am J Obstet Gynecol* 1996; 174:1224-1229.

Guzick, D.S, Tabott, E. Sutton-Tyrrell, K., Herzog, H.C., Kuller, L.H. and Wolfson, S.K. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case control study. *American Journal of Obstetric and Gynaecology* 1996; 174, 1224-1232.

Hague WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. *Clin Endocrinol* 1990; 33:501-510.

Hatch R, Rosenfield RL Kim MH, et al. Hirsutism: Implications, etiology, and management. *Am J Obstet Gynecol* 1981; 140:815-83.

Hayes FJ, Taylor AE, Martin KA, et al. Use of a gonadotropin- releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: Assessment of neuroendocrine and androgen dynamics. *J Clin Endocrinol Metab* 1998; 83:2343-2349.

Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. *Clin Endocrinol* 1994; 41:463-71.

Holte J, Bergh T, Gennarelli G, et al. The Independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotropins and sex steroids in premenopausal women. *Clin Endocrinol* 1994; 41: 473-481.

Holte, J., Bergh, T., Berne, C. and Lithell, H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. *Clinical Endocrinology*, 1994; 41, 463-471.

Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. *Gynaecol Endocrinol* 1987; 1: 233-245.

Ibanez L, De Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. *J Clin Endocrinol Metab* 2003; 88:4720-4.

- Jialal I, Naiker, Reddi K, Moddley J, Joubert SM.** Evidence for insulin resistance in non-obese patients with polycystic ovarian disease. *J Clin Endocrinol Metab* 1987; 64: 1066-72.
- Judd HL, Parker DC, Siler TM, et al.** The nocturnal rise of plasma testosterone in pubertal boys. *J Clin Endocrinol Metab* 1974; 38: 710.
- Judd S. Terry A. Petrucco M and White G:** The source of pulsatile secretion of progesterone during the human follicular phase. *J Clin Endocrinol Metab* 1992; 74, 299-305.
- Kalra SP.** Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone- releasing hormone discharge. *Endocr Rev* 1993; 14: 507-538.
- Kelly CJG Connell JMC, Cameron IT, et al.** The long-term health consequences of polycystic ovary syndrome. *Br J Obstet Gynaecol* 2000; 107:1327-38.
- Kesner JS, Kaufman JM, Wilson RC, et al.** The effect of morphine on the electrophysiological activity of the hypothalamic luteinizing hormone pulse generator in the Rhesus monkey. *Neuroendocrinology* 1986; 43: 686-688.
- Kiddly DS, Sharp PS, White DM, et al.** Differences in clinical and endocrine features between obese and nonobese subjects with polycystic ovary syndrome; An analysis of 263 consecutive cases. *Clin Endocrinol* 1990; 32:213-220.
- Kiddy DS, Hamilton-Fairley D, Seppala M, et al.** Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries Correlation with serum insulin and insulin-like growth factor I. *Clin Endocrinol* 1989; 31:757-763.
- Kissebah AH, Vydelingum N, Murray R, et al.** Relation of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab* 1982; 54:254-260.
- Krassas GE, Pontikides N, Kaltsas T, et al.** Disturbances of menstruation in hypothyroidism. *Clin Endocrinol* 1999; 50:655-659.
- Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G.R., Lupien, P.J. & Despres, J.P.** Small, dense LDL particles as a

predictor of the risk of ischemic heart disease in men. *Circulation* 1997; 95, 69-75.

Laughlin GA, Morales AJ, Yen SS. Serum leptin levels in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1997; 82:1692-1696.

Lee G, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptors in diabetic mice. *Nature* 1996; 379: 632.

Lefebvre P, Binger J, Renard E, et al. Influences of weight body fat patterning and nutrition on the management of PCOS. *Hum Reprod* 12 (Suppl. 1) 1997; 72-81.

Lefebvre, P., Bringer, J., Renard, E., Boulet, F., Clouet, S. & Jaffiol, C. Influences of weight, body fat patterning and nutrition on the management of PCOS. *Human Reproduction* 1997; 12, (Suppl. 1), 72-81;

Legro R, Strauss J. Molecular progress in infertility: Polycystic ovary syndrome. *Fertil Steril* 2003; 78: 569-576.

Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1998; 83:2694- 2698.

Legro RS, Kusanman AR, Dodson WC, et al. Prevalence and predictors of risk type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 1999; 84:165-169.

Legro RS. The genetics of obesity: Lessons for polycystic ovary syndrome. *Ann NY Acad Sci* 2000; 900: 193-202.

Legro RS. The genetics of Polycystic ovary syndrome. *Am J Med* 1995; 98:9S-16S.

Legro, R.S., Blanche, P., Krauss, R.M. and Lobo, R.A. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. *Fertility Sterility*, 1999; 72, 990-995.

Leibowitz SF, Akabayashi A, Alexander JT, et al. Gonadal steroids and hypothalamic galanin and neuropeptide Y: Role eating behavior

and body weight control in female rats. *Endocrinology* 1998; 139: 1771-1780.

Leondires MP, Berga SL. Role of GnRH drive in the pathophysiology of polycystic ovary syndrome. *J Endocrinol Invest* 1998; 21: 476-485.

Levin JH, Carmin E, Lobo RA. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with ault-onset congenital adrenal hyperplasia? *Fertil Steril* 1991; 56:635-640.

Li Q, Niwa K and Hunter MG: Effects of 17beta-estradiol on in vitro maturation of pig oocytes in protein-free medium. *J Reprod Dev* 1998; 50, 305-313.

Licinio J, Negratildeo AB, Mantzoros C, et al. Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. *Proc Natl Acad Sci USA* 1998; 95: 2541-2546.

Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. *Ann intern Med* 2000; 132: 989-93.

Lobo RA, Shoupe D, Chang SP, et al. The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome. *Am J Obstet Gynecol* 1984; 148:423-428.

Loucks TL, Talbott EO, McHugh KP, et al. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? *Fertil Steril* 2000; 74: 547-52;.

Mahabeer S, Naidoo C, Norman RJ, et al. Metabolic Profiles and lipoprotein lipid concentrations in nonobese and obese patients with polycystic ovary syndrome. *Horm Metab Res* 1990; 22: 537-540.

Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. *N Engl J Med* 1990; 322: 882-889.

Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1997; 82:1687-1691.

- Mather KJ, Kwan F, Corenblum B.** Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. *Fertil Steril*. 2000; 73: 150-156.
- Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Tokunaga K.** Pathophysiology and pathogenesis of visceral fat obesity. *Ann N Y Acad Sci* 1995; 748: 399-406.
- McNamara, J.R. Jenner, J.L., Li, Z., Wilson, P.W.F. and Shaefer, E.J.** Change in LDL particle size is associated with change in plasma triglycerides concentration. *Arteriosclerosis and Thrombosis* 1992; 12, 1284-1290.
- Mekki N, Christofilis MA, Charbonnier M, Atlan-Gepner C, Defoort C, Juhel C, et al.** Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. *J Clin Endocrinol Metab* 1999; 84:184-91.
- Meldrum DR, Abraham GE.** Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. *Obstet Gynecol* 1979; 53:36-43.
- Michelmore KF, Blen AH, Dunger DB, et al.** Polycystic ovaries and associated clinical and biochemical features in young women. *Clin Endocrinol* 1999; 51:779-786.
- Mitchell BD, Stern MP, Haffner SM, et al.** Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic Whites. San Antonio Heart Study. *Am J Epidemiol* 1990; 131:423-433.
- Morales AJ, Laughlin GA, Butzow T et al.** Insulin, somatotrophic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features. *J Clin Endocrinol Metab* 1996; 81: 2854-2864.
- Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN.** Ovarian stimulation and borderline ovarian tumors: a case- control study. *Fertil Steril* 1998; 70: 1049-1055.
- Nagamani M, Osuampke C, Kelder ME.** Increased bioactive luteinizing hormone levels and bio/immuno ratio in women with hyperthecosis of the ovaries: Possible role of hyperinsulinemia. *J Clin Endocrinol Metab* 1999; 84:1685-1689.

- Nagamani M, Urban RJ.** Increased expression of messenger ribonucleic acid encoding cytochrome p450 cholesterol side-chain cleavage and p450 17-alpha-hydroxylase enzymes in ovarian hyperthecosis. *Fertil Steril* 1999; 71:328-333.
- Nagamani M, Van Dinh T, Kelder ME.** Hyperinsulinemia in hyperthecosis of the ovaries. *Am J Obstet Gynecol* 1986; 154: 384-389.
- Nelson LR and Bulun SE:** Estrogen production and action. *J Am Acad Dermatol* 2001; 45, S116-S124.
- Nestler JE, Powers LP, Matt DW, et al.** A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1991; 72:83-89.
- Norman, R.J., Hague, W.M., Masters, S.C. and Wang, X.J.** Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. *Human Reproduction* 1995; 10, 2258-2261.
- Oberfield SE.** Metabolic lessons from the study of young adolescents with polycystic ovary syndrome-is insulin indeed, the culprit? (editorial) *J Clin Endocrinol Metab* 2000; 85;3520-5.
- Pache TD, Wladimiroff JW, Hop WC, et al.** How to discriminate between normal and polycystic ovaries: Transvaginal US study. *Radiology* 1992; 183:421-423.
- Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M, Pasquali R.:** Plasma ghrelin, obesity, and the polycystic ovary syndrome: Correlation with insulin resistance and androgen levels. *J Clin Endocrinol Metab* 2002; 87: 5625-5629.
- Palter SF, Tavares AB, Hourvitz A, Veldhuis JD and Adashi EY:** Are estrogens of import to primate/human ovarian folliculogenesis? *Endocr Rev* 2001; 22,389-424.
- Paradisi G, Steinberg HO, Hempfling A, et al.** Polycystic ovary syndrome is associated with endo-thelial dysfunction. *Circulation* 2001; 103: 1410-15.

- Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M and Morselli-Labate AM:** Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2000; 85:2767-2774.
- Pasquali, R., Casimirri, F., Venturoli, S., Antonio, M., Morselli, L., Reho, S., Pezzoli, A. & Paradisi, R.** Body fat distribution has weight- independent effects on clinical, hormonal, and meabolic features of women with polycystic ovary syndrome. *Metablism* 1994; 43, 706-713.
- Pastor CL, Griffin- Korf ML, Aloï JA, et al.** Polycystic ovary syndrome: Evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. *J Clin Endocrinol Metab* 1998; 83: 582-590.
- Patsch JR, Prasad S, Gotto AM Jr., Patsch W.** High density lipoprotein. Relationship of the plasma of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. *J Clin Inves* 1987; 80; 341-7.
- Peppard HR, Marfori J, Juorno MJ, Nestler JE.** Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. *Diabetes Care* 2001; 24: 1050-1052.
- Petraglia F, Locatelli V, Penalva A, et al.** Gonadal steroid modulation of naloxoneinduced luteinizing hormone secretion in the rat. *J Endocrinol* 1984; 101: 33.
- Pierpoint T, McKeigue PM, Isaacs AJ, et al.** Mortality of women with polycystic ovary syndrome at long-term follow-up. *J Clin Epidemiol* 1998; 51:581-586.
- Pierpoint, T., McKeigue, P.M., Isaacs, A.J., Wild, S.H. and Jacobs, H.S.** Mortality of women with polycystic ovary syndrome at long-term follow-up. *Journal of clincial Epidemiology* 1998; 51, 581-586.
- Pirwany IR, Fleming R, Greer IA, et al.** Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic

and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54:447-53.

Palmert MR, Radovick S, Boepple PA. The impact of reversible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty. J Clin Endocrinol Metab 1998; 83: 1091-1096.

Plant TM. A striking difference in the gonadotropin response to gonadectomy during infantile development in the rhesus monkey (*Macaca mulatta*). Endocrinology 1986; 119: 539-545.

Polson DW, Adams J, Wadsworth J, et al. Polycystic ovaries-a common finding in normal women. Lancet 1988; 1: 870-872.

Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries- a common finding in normal women. Lancet 1998; i: 870-872.

Polson DW. Polycystic ovary syndrome and epilepsy- gynaecological perspective. Seizure 2003; 12: 397-402.

Prelevic, G.M. Insulin resistance in polycystic ovary syndrome. Current Opinion in Obstetric and Gynaecology 1997; 9, 193-201.

Prevot V, Croix D, Rialas CM, et al. Estradiol coupling to endothelial nitric oxide stimulates gonadotropin- releasing hormone release from rat median eminence via a membrane receptor. Endocrinology 1999; 140:652-659.

Pugeat, M., Moulin, P., Cousin, P., Fimbel, S., Nicolas, M.H., Crave, J.C.& Lejeune, H. Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. Journal of Steroid Biochemistry and Molecular Biology 1995; 53:567-572.

Quigley ME, Sheehan KL, Casper RF, et al. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1980; 50: 949.

Rajkhowa M, Glass MR, Rutherford AJ. Et al. Polycystic ovary syndrome: a risk factor for cardiovascular disease. Br J Obstet Gynaecol 2000; 107:11-18.

- Rajkhowa M, Neary RH, Kumpatla P, et al.** Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. *J Clin Endocrinol Metab.* 1997; 82:3389-3394.
- Rebar R, Judd HL, Yen SS, et al.** Characterization of the inappropriate gonadotropin secretion polycystic ovary syndrome. *J Clin Invest* 1976; 57: 1320-1329.
- Ridker PM, Hennekens CH, Buring JE, Rifai N.** C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med.* 2000; 342:836-843.
- Robinson S, Henderson AD, Gelding SV, et al.** Dyslipidaemia is associated with insulin resistance in women with polycystic ovary syndrome. *Clin Endocrinol* 1996; 44:277-84.
- Robinson S, Henderson AD, Gelding SV, et al.** Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. *Clin Endocrinol* 1996; 44:277-284.
- Robinson S, Rodin DA, Deacon A, et al.** Which hormone tests for the diagnosis of polycystic ovary syndrome? *Br J Obstet Gynaecol* 1992; 99:232-238.
- Rossmannith WG, Marks DL, Clifton DK, et al.** Induction of galanin gene expression in gonadotropin-releasing hormone neurons with puberty in the rat. *Endocrinology* 1994; 135:1401-1408.
- Roth C, Jung H, Kim K, et al.** Involvement of gamma amino butyric acid (GABA) in the postnatal function of the GnRH pulse generator as determined on the basis of GnRH and GnRH- receptor gene expression in the hypothalamus and the pituitary. *Exp Clin Endocrinol Diabetes* 1997; 105: 353-358.
- Rotterdam ESHRE / ASRM-Sponsored PCOS Consensus Workshop Group.** Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 2003; 81: 19-25.
- Sabir N, Sermez Y, Kazil S, Zencir M.** Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. *Eur J Ultrasound* 2001; 14:121-8.

- Sam S, Legro RS, Bentley-Lewis R, Dunaif A.** Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005; 90: 4797-802.
- Sampson, M., Kong, C., Patel, A., Unwin, R. and Jacobs, H.S.** Ambulatory blood pressure profiles and plasminogen activator inhibitor (Pai-1) Activity in lean women with and without the polycystic ovary syndrome. *Clinical Endocrinology* 1996; 45, 623-629.
- Schwartz MW, Baskin DG, Bukowski TR, et al.** Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. *Diabetes* 1996; 45:531-535.
- Segos C, Markianos M, Aravantinos D.** Increased dopamine turnover in women with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol* 1989; 33:229-234.
- Selby, J.V., Austin, M.A., Newman, B., Zhang, D., Quesenberry, C.P. Jr, Mayer, E.J. and Krauss, R.M.** LDL subclass phenotypes and the insulin resistance syndrome in women. *Circulation* 1993; 88, 381-387.
- Sempos CT, Cleeman II, Carroll MD, et al.** Prevalence of high blood cholesterol among U.S. adults. An update base on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. *JAMA* 1993; 269; 3009-3014.
- Senoz, S., Ozaksit, G., Turhan, N.O., Gulekli, B. & Gokmen, O.** Lipid profiles in women with hirsutism and polycystic ovaries. *Gynaecology Endocrinology* 1994; 8, 33-37.
- Shulntan A, Ghetler Y, Beyth Y and Ben-Nun I:** The significance of an early (premature) rise of plasma progesterone in in vitro fertilization cycles induced by a “long protocol” of gonadotropin releasing hormone analogue and human menopausal gonadotropins. *J Assist Reprod Genet* 1996; 13,207-211.
- Sibley DR, Monsma Fj Jr.** Molecular biology of dopamine receptors. *Trends Biochem Sci* 1992; 13:61-68.

- Sir- Petermann T, Piwonka V, Perez F, et al.** Are circulating leptin and luteinizing hormone synchronized in patients with polycystic ovary syndrome? *Hum Reprod* 1999; 14: 1435-1439.
- Slowinska- Srzednicka J, Zgliczynski S, Wierzbicki M, et al.** The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. *J Endocrinol Invest* 1991; 14:569-575.
- Slowinska- Srzednicka J, Zgliczynski S, Wierzbicki M, et al.** The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. *J Endocrinol Invest* 1991; 14: 569-75.
- Solomon CG.** The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. *Endocrinol Metab Clin North Am* 1999; 28: 247-63.
- Speiser PW, Serrat J, New MI, et al.** Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1992; 75:1421-1424.
- Spinder T, Spijkstra JJ, Gooren LJ, et al.** Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women. *J Clin Endocrinol Metab* 1989; 68:200-207.
- Stanley BG, Kyrkouli SE, Lampert S, et al.** Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity. *Peptides* 1986; 7: 1189-1192.
- Stein IF, Leventhal ML.** Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935; 29: 181-191.
- Stephens TW, Basinski M, Bristow PK, et al.** The role of neuropeptide Y in the antiobesity action of the obese gene product. *Nature* 1995; 377:530-532.
- Stephens TW: Life without neuropeptide Y.** *Nature* 1998; 381: 377-378.
- Stuart CA, Pate CJ, Peters EJ.** Prevalence of acanthosis nigricans in an unselected population. *Am J Med* 1989; 87:269-272.

- Suzuki R, Watanabe S, Hirai Y, Akiyama K, Nishide T, Matsushima Y.** Abdominal wall index, estimated by ultrasonography, for assesment of the ratio of visceral fat to subcutaneous fat in the abdomon. *Am J Med* 1993; 95:309-14.
- Swanson M, Sauerbrei EE, Cooperberg PL.** Medical implications of ultrasonically detected polycystic ovaries. *J Clin Ultrasound* 1981; 9:219-222.
- Takahashi K, Eda Y, Okada S, et al.** Morphological assessment of polycystic ovary using transvaginal ultrasound. *Hum Reprod* 1993; 8:844-849.
- Talbott E, Clerici A, Berga SL, et al.** Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case- control study. *J Clin Epidemiol* 1998; 51: 415-422.
- Talbott EO, Guzick DS, Sutton- Tyrrell K, et al.** Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. *Arterioscl Thromb Vasc Biol* 2000; 20; 2414-2421.
- Talbott EO, Zborowski JV, Sutton-Tyrell K, et al.** Cardiovascular risk in women with polycystic ovary syndrome. *Obstet Gynecol Clin North Am* 2001; 28: 111-33.
- Talbott, E., Guzick, D., Clerici, A., Berga, S., Detre, K., Weimer, K. and Kuller, L.** Coronary heart disease risk factors in women with polycysitic ovary syndrome. *Arteriosclerosis Thrombosis and Vascular Biology* 1995; 15, 821-826.
- Taylor AE, McCourt B, Martin KA, et al.** Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1997; 82:2248-2256.
- Taylor AE.** Polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 1998; 27:877-902.
- Tribble, D.L., Holl, L.G., Wood, P.D. & Krauss, R.M.** Variations in the oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. *Atherosclerosis* 1992; 93:189-199.

- Tropeano G, Liberale, I Vuolo IP, et al.** Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin- like growth factor I and insulin levels in women with polycystic ovary syndrome. *J Endocrinol Invest* 1997; 20:220-224.
- Turley ML, Skeaff CM, Mann JI, Cox B.** The effect of a low-fat high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. *Eur J Clin Nutr.* 1998; 52:728-732.
- Urbanek M, Legro RS, Driscoll DA, et al:** Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. *Proc Natl Acad Sci U S A* 96: 8573-8578, 1999.
- Van Hooff MH, van der Meer M, Lambalk CB, et al.** Variation of luteinizing hormone and androgens in oligomenorrhea and its implications for the study of polycystic ovary syndrome. *Hum Reprod* 1999; 14:1684-1689.
- Van Wely M. Bayram N, Van der Veen F and Bossuyt PM:** Predictors for treatment failure after laparoscopic electrocautery of the ovaries in women with clomiphene citrate resistant polycystic ovary syndrome. *Hum Reprod*; 2005.
- Velazquez ME, Bellabarba GA, Mendoza S, et al.** Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. *Fertil Steril* 2000; 74:1159-63.
- Vicino M, Loverro G, Bettocchi S, Simonetti S, Mei L and Selvaggi L:** Predictive value of serum androstendione basal levels on the choice of gonadotropin or laparoscopic ovarian electrocautery as ovulation induction in clomiphene citrate-resistant patients with polycystic ovary syndrome. *Gynecol Endocrino* 2000; 14,42-49.
- Von Eckardstein S, von Eckardstein A, Bender HG, et al.** Elevated low-density lipoprotein- cholesterol in women with polycystic ovary syndrome. *Gynecol Endocrinol* 1996; 10:311-318.
- Waggoner W, Boots LR, Azziz R.** Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: A populational study. *Gynecol Endocrinol* 1999; 13:394-400.

- Wahrenberg H, EK, I Reynsidottir S, et al.** Divergent effects of weight reduction and oral contraception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1999; 84: 2182-2187.
- Wajchenberg BL, Achando SS, Okada H, et al.** Determination of the source (s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization: Comparison with the dexamethasone suppression test. *J Clin Endocrinol Metab* 1986; 63:1204-1210.
- Wei M, Mitchell BD, Haffner SM, Stern MP.** Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans: The San Antonio Heart Study. *Am J Epidemiol* 1996; 144: 1058-1065.
- Wheeler MJ, Lowy C.** Warning on serum testosterone measurement {letter}. *Lancet* 1987; 2:514-515.
- Widwman L, Kaminsky LA, Whaley MH.** Postprandial lipemia in obese men with abdominal fat patterning. *J Sport Med Phys fitness* 1996; 36:204-10.
- Wijeyaratne CN, Balen AH, Barth JH et al.** Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among south Asians and Caucasians: is there a difference? *Clin Endocrinol* 2002, 57: 343-350.
- Wild RA, Bartholomew MJ.** The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome. *Am J Obstet Gynecol* 1988; 159: 423-427.
- Wild RA, Umstot ES, Andersen RN, et al.** Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. *Am J Obstet Gynecol* 1983; 146:602-606.
- Wild, R.A., Painter, P., Coulson, P., Carruth, K. and Ranney, G.** Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. *Journal of Clinical Endocrinology and Metabolism* 1985; 61, 946-951.

- Williamson K, Gunn AJ, Johnson N, Milsom SR.** The impact of ethnicity on the presentation of polycystic ovarian syndrome. *Aust NZJ Obstet Gynaecol* 2001; 41: 202-206.
- Wilson PW, Abbott RD, Castelli WP.** High density lipoprotein cholesterol and mortality. The Framingham Heart Study. *Arteriosclerosis* 1988; 8:737-741.
- Witkin JW.** Morphology of luteinizing hormone- releasing hormone neurons as a function of age and hormonal condition in the male rat. *Neuroendocrinology* 1989; 49: 344-348.
- Wladstreich J, Santoro NF, Hall JE, et al.** Hyperfunction of the hypothalamicpituitary axis in women with polycystic ovarian disease: Indirect evidence of a partial gonadotroph desensitization. *J Clin Endocrinol Metab* 1988; 66: 165-172.
- Wortsman J, Wherenberg WB, Gavin JR, et al.** Elevated levels of plasma-endorphin and melanocyte stimulating hormone in polycystic ovary syndrome. *Obstet Gynecol* 1984; 63: 630-634.
- Xu B, Pu S, Kalra PS, et al.** An interactive physiological role of neuropeptide Y and galanin in pulsatile pituitary luteinizing hormone secretion. *Endocrinology* 1996; 137: 5297-5302.
- Yamamoto M, Egusa G, Hara H, Yamakido M.** Association of intra-abdominal fat and carotid atherosclerosis in non-obese middle aged men with normal glucose tolerance. *Int J Obesity* 1997; 21; 948-51.
- Yen SS, Lasley BL, Wang CF, et al.** The operating characteristics of the hypothalamic-pituitary system during the menstrual cycle and observations of biological action of somatostatin. *Recent Prog Horm Res* 1975; 31:32-363.
- Yen SS, Vela P, Rankin J.** Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. *J Clin Endocrinol Metab* 1970; 30: 435-442.
- Yen SSC.** Polycystic ovary syndrome. In Yen SSC, Jaffe RB, Barbieri RL (eds). *Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management*, ed 4. Philadelphia, WB Saunders 1999; p 436-477.

- Yu WH, Kimura M, Walczewska A, et al.** Role of leptin in hypothalamic-pituitary function. *Proc Natl Acad Sci USA* 1997; 94: 1023-1028.
- Zaidi J, Campbell S, Pittrof R, et al.** Ovarian stromal blood flow in women with polycystic ovaries- a possible new marker for diagnosis? *Hum Reprod* 1995; 10: 1992-1996,.
- Zawadzki JK, Dunaif A.** Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In : Dunaif A, Givens JR, Haseltine FP, Merriman GR. (eds) *Polycystic Ovary Syndrome*. Oxford; Blackwell, 1992; 377-384.
- Zawadzki JK, Dunaif A.** Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In Dunaif A, Givens JR, Haseltine FP, et al (eds): *Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism*, vol 4. Boston, Blackwell Scientific 1992; P 377-384.
- Zhang Y, Proenca R, Maffei M, et al.** Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994; 372: 425.